Mechanisms involved in chemotherapy-induced apoptosis and their implications in cancer chemotherapy

International Journal of Hematology

Volumn 68, Issue 1, 1998, Pages 29-43

  Kamesaki, H ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Apoptosis; Cancer; Chemotherapy

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUCOCORTICOID; METHOTREXATE; MITOMYCIN C; PACLITAXEL; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; CANCER CHEMOTHERAPY; CELL DEATH; CELL KILLING; CYTOTOXICITY; DRUG INDUCED DISEASE; ENZYME ACTIVE SITE; GENE INDUCTION; GENOTOXICITY; IMMEDIATE EARLY GENE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY;

EID: 0032125905     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00038-3     Document Type: Review

References (154)

1. Epstein R.J. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol. 8:1990;2062-2084.
2. Wyllie A.H., Kerr J.F.R., Currie A.R. Cell death: the significance of apoptosis. Int Rev Cytol. 68:1980;251-306.
3. Sen S., D'Incalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett. 307:1992;122-127.
4. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
5. Lowe S.W., Bodis S., Bardeesy N.et al. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harbor Symp Quant Biol. 59:1994;419-426.
6. Kaufmann S.H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 49:1989;5870-5878.
7. Walker P.R., Smith C., Youdale T.et al. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res. 51:1991;1078-1085.
8. Shinomiya N., Shinomiya M., Wakiyama H.et al. Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. Exp Cell Res. 210:1994;236-242.
9. Havrilesky L.J., Elbendary A., Hurteau J.A.et al. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol. 85:1995;1007-1010.
10. Huschtscha L.I., Bartier W.A., Ross C.E.A.et al. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer. 73:1996;54-60.
11. Meyn R.E., Stephens L.C., Hunter N.R.et al. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol. 33:1994;410-414.
12. Meyn R.E., Stephens L.C., Hunter N.R.et al. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs. 6:1995;443-450.
13. Moreira L.F., Naomoto Y., Hamada M.et al. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res. 15:1995;639-644.
14. Gorczyca W., Bigman K., Mittelman A.et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia. 7:1993;659-670.
15. Schwartz L.M., Smith S.W., Jones M.E.et al. Do all programmed cell deaths occur via apoptosis? Proc Natl Acad Sci USA. 90:1993;980-984.
16. Duvall E., Wyllie A.H. Death and the cell. Immunol Today. 7:1986;115-119.
17. Schwartz L.M., Osborne B.A. Programmed cell death, apoptosis and killer genes. Immunol Today. 14:1993;582-590.
18. Kerr J.F., Searle J. The digestion of cellular fragments within phagolysosomes in carcinoma cells. J Pathol. 108:1972;55-58.
19. Searle J., Lawson T.A., Abbott P.J.et al. An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol. 116:1975;129-138.
20. Wyllie A.H. The biology of cell death in tumours. Anticancer Res. 5:1985;131-136.
21. Schwartzman R.A., Cidlowski J.A. Glucocorticoid-induced apoptosis of lymphoid cells. Int Arch Allergy Immunol. 105:1994;347-354.
22. Smyth M.J., Obeid L.M., Hannun Y.A. Ceramide: a novel mediator of apoptosis. Adv Pharmacol. 41:1997;133-154.
23. Meisenholder G.W., Martin S.J., Green D.R.et al. Events in apoptosis. Acidification is downstream of protease activation and BCL-2 protection. J Biol Chem. 271:1996;16260-16262.
24. Kaufmann S.H. Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today. 2:1996;298-303.
25. Saunders J.W. Jr. Death in embryonic systems. Science. 154:1966;604-612.
26. Lockshin R.A. Programmed cell death. Activation of lysis of a mechanism involving the synthesis of protein. J Insect Physiol. 15:1969;1505-1516.
27. Rosl F. A simple and rapid method for detection of apoptosis in human cells. Nucleic Acids Res. 20:1992;5243.
28. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
29. Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1993;1945-1951.
30. Casciola-Rosen L., Nicholson D.W., Chong T.et al. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med. 183:1996;1957-1964.
31. Erhardt P., Cooper G.M. Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL. J Biol Chem. 271:1996;17601-17604.
32. Martin S.J., Reutelingsperger C.P., McGahon A.J.et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 182:1995;1545-1556.
33. Koopman G., Reutelingsperger C.P., Kuijten G.A.et al. Annexin V for cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1994;1415-1420.
34. Gold R., Schmied M., Giegerich G.et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest. 71:1994;219-225.
35. Grasl-Kraupp B., Ruttkay-Nedecky B., Koudelka H.et al. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis and autolytic cell death: a cautionary note. Hepatology. 21:1995;1465-1468.
36. Schwartz H.S., Sodergren J.E., Sternberg S.S.et al. Actinomycin D: effects on Ridgway osteogenic sarcoma in mice. Cancer Res. 26:1966;1873-1879.
37. Li X., Gong J., Feldman E.et al. Apoptotic cell death during treatment of leukemias. Leuk Lymphoma. 13:1994;65-70.
38. Wyllie A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 284:1980;555-556.
39. Wyllie A.H., Morris R.G., Smith A.L.et al. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol. 142:1984;67-77.
40. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
41. Golstein P., Marguet D., Depraetere V. Homology between reaper and the cell death domains of Fas and TNFR1. Cell. 81:1995;185-186.
42. Grether M.E., Abrams J.M., Agapite J.et al. The head involution defective gene of Drosophila melanogaster functions in programmed cell death. Genes Dev. 9:1995;1694-1708.
43. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G.et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-318.
44. Chinnaiyan A.M., O'Rourke K., Tewari M.et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:1995;505-512.
45. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell. 81:1995;495-504.
46. Stanger B.Z., Leder P., Lee T.H.et al. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:1995;513-524.
47. Tartaglia L.A., Ayres T.M., Wong G.M.et al. A novel domain within the 55kd TNF receptor signals cell death. Cell. 74:1993;845-853.
48. Suda T., Takahashi T., Golstein P.et al. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
49. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
50. Muller M., Strand S., Hug H.et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 99:1997;403-413.
51. Friesen C., Herr I., Krammer P.H.et al. Involvement of the CD95(APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 2:1996;574-577.
52. Mesner P.W. Jr., Budihardjo I.I., Kaufmann S.H. Chemotherapy-induced apoptosis. Adv Pharmacol. 41:1997;461-499.
53. Kaufmann S.H., Desnoyers S., Ottaviano Y.et al. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:1993;3976-3985.
54. Martin S.J., Lennon S.V., Bonham A.M.et al. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol. 145:1990;1859-1867.
55. Yonish-Rouach E., Resnitzky D., Lotem J.et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
56. Clarke A.R., Purdie C.A., Harrison D.J.et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
57. Lowe S.W. Cancer therapy and p53. Curr Opin Oncol. 7:1995;547-553.
58. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
59. El-Deiry W.S., Tokino T., Velculescu V.E.et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
60. Di Leonardo A., Linke S.P., Clarkin K.et al. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
61. Waldman T., Lengauer C., Kinzler K.W.et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
62. Kimura Y., Furuhata T., Shiratsuchi T.et al. GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene. 15:1997;1369-1374.
63. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 80:1992;879-886.
64. Yang E., Korsmeyer S.J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 88:1996;386-401.
65. Boise L.H., Gonzalez-Garcia M., Postema C.E.et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
66. Lin E.Y., Orlofsky A., Berger M.S.et al. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol. 151:1993;1979-1988.
67. Kozopas K.M., Yang T., Buchan H.L.et al. MCL1, a gene expressed in programmed myeloid differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 90:1993;3516-3520.
68. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
69. Farrow S.N., White J.H.M., Martinou I.et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature. 374:1995;731-733.
70. Chittenden T., Harrington E.A., O'Connor R.et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature. 374:1995;733-736.
71. Kiefer M.C., Brauer M.J., Powers V.C.et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature. 374:1995;736-739.
72. L and Bcl-2, displaces Bax and promotes cell death. Cell. 80:1995;285-291.
73. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 92:1995;4507-4511.
74. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
75. Del Peso L., Gonzalez-Garcia M., Page C.et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 278:1997;687-689.
76. Datta S.R., Dudek H., Tao X.et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
77. L forms an ion channel in synthetic lipid membranes. Science. 385:1997;353-357.
78. Schlesinger P.H., Gross A., Yin X.-M.et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA. 94:1997;11357-11362.
79. Wang H.G., Rapp U.R., Reed J.C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 87:1996;629-638.
80. Shibasaki F., Kondo E., Akagi T.et al. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature. 386:1997;728-731.
81. Chinnaiyan A.M., O'Rourke K., Lane B.R.et al. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science. 275:1997;1122-1126.
82. Jarvis W.D., Grant S., Kolesnick R.N. Ceramide and the induction of apoptosis. Clin Cancer Res. 2:1996;1-6.
83. Haimovitz-Friedman A., Kolesnick R.N., Fuks Z. Ceramide signaling in apoptosis. Br Med Bull. 53:1997;539-553.
84. Obeid L.M., Linardic C.M., Karolak L.A.et al. Programmed cell death induced by ceramide. Science. 259:1993;1769-1771.
85. Jarvis W.D., Kolesnick R.N., Fornari F.A.et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA. 91:1994;73-77.
86. Wiegmann K., Schutze S., Machleidt T.et al. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell. 78:1994;1005-1015.
87. Bose R., Verheij M., Haimovitz-Friedman A.et al. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 82:1995;405-414.
88. Jaffrezou J.P., Levade T., Bettaieb A.et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15:1996;2417-2424.
89. Strum J.C., Small G.W., Pauig S.B.et al. 1-β-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem. 269:1994;15493-15497.
90. Herr I., Wilhelm D., Bohler T.et al. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16:1997;6200-6208.
91. Ellis H.M., Horvitz H.R. Genetic control of programmed cell death in the nematode C. elegans. Cell. 44:1986;817-829.
92. Yuan J., Shaham S., Ledoux S.et al. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell. 75:1993;641-652.
93. Kumar S., Kinoshita M., Noda M.et al. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1β-converting enzyme. Genes Dev. 8:1994;1613-1626.
94. Wang L., Miura M., Bergeron L.et al. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell. 78:1994;739-750.
95. Fernandes-Alnemri T., Litwack G., Alnemri E.S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem. 269:1994;30761-30764.
96. Tewari M., Quan L.T., O'Rourke K.et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 81:1995;801-809.
97. Faucheu C., Diu A., Chan A.W.E.et al. A novel human protease similar to the interleukin-1β converting enzyme induces apoptosis in transfected cells. EMBO J. 14:1995;1914-1922.
98. Kamens J., Paskind M., Hugunin M.et al. Identification and characterization of ICH-2, a novel member of the interleukin-1β-converting enzyme family of cysteine proteases. J Biol Chem. 270:1995;15250-15256.
99. Fernandes-Alnemri T., Takahashi A., Armstrong R.et al. Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res. 55:1995;6045-6052.
100. Faucheu C., Blanchet A.M., Collard-Dutilleul V.et al. Identification of a cysteine protease closely related to interleukin-1β-converting enzyme. Eur J Biochem. 236:1996;207-213.
101. Muzio M., Chinnaiyan A.M., Kischkel F.C.et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827.
102. Fernandes-Alnemri T., Armstrong R.C., Krebs J.et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADDlike domains. Proc Natl Acad Sci USA. 93:1996;7464-7469.
103. Srinivasula S.M., Fernandes-Alnemri T., Zangrilli J.et al. The Ced-3/interleukin 1β converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. J Biol Chem. 271:1996;27099-27106.
104. Smith G.K., Duch D.S., Dev I.K.et al. Metabolic effects and kill of human T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase. Cancer Res. 52:1992;4895-4903.
105. Chinnaiyan A.M., Orth K., O'Rourke K.et al. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem. 271:1996;4573-4576.
106. Lazebnik Y.A., Kaufmann S.H., Desnoyers S.et al. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371:1994;346-347.
107. Nicholson D.W., Ali A., Thornberry N.A.et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
108. Ibrado A.M., Huang Y., Fang G.et al. Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ. 7:1996;1087-1094.
109. Tata J.R. Requirement for RNA and protein synthesis for induced regression of the tadpole tail in organ culture. Dev Biol. 13:1966;77-94.
110. Hallahan C., Young D.A., Munck A. Time course of early events in the action of glucocorticoids on rat thymus cells in vitro. Synthesis and turnover of a hypothetical cortisol-induced protein inhibition of glucose metabolism and a presumed ribonucleic acid. J Biol Chem. 248:1973;2922-2927.
111. Buttyan R., Zakeri Z., Lockshin R.et al. Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol. 2:1988;650-657.
112. Estus S., Zaks W.J., Freeman R.S.et al. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol. 127:1994;1717-1727.
113. Kharbanda S., Datta R., Kufe D. Induction of c-fos gene expression by arabinofuranosylcytosine in human KG-1 leukemia cells. Cancer Commun. 2:1990;409-414.
114. Smeyne R.J., Vendrell M., Hayward M.et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature. 363:1993;166-169.
115. Koechli O., Schaer G.N., Seifert B.et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet. 344:1994;1647-1648.
116. Rutz H.P. Cancer therapy meets p53. New Engl J Med. 331:1995;1314-1315.
117. Makris A., Powles T.J., Dowsett M.et al. p53 protein overexpression and chemosensitivity in breast cancer. Lancet. 345:1995;1181-1182.
118. Mathieu M.C., Koscielny S., Le Bihan M.L.et al. p53 protein overexpression and chemosensitivity in breast cancer. Institute Gustave-Roussy Breast Cancer Group. Lancet. 345:1995;1182.
119. Petty R.D., Cree I.A., Sutherland L.A.et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun. 199:1994;264-270.
120. Lowe S.W., Ruley H.E., Jacks T.et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
121. Lowe S.W., Bodis S., McClatchey A.et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
122. Fan S., el-Deiry W.S., Bae I.et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:1994;5824-5830.
123. Fan S., Smith M.L., Rivet D.J.et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1995;1649-1654.
124. Mueller H., Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res. 16:1996;3845-3848.
125. Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151-157.
126. Miyashita T., Reed J.C. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:1992;5407-5411.
127. Walton M.I., Whysong D., O'Connor P.M.et al. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53:1993;1853-1861.
128. Fisher T.C., Milner A.E., Gregory C.D.et al. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 53:1993;3321-3326.
129. Hashimoto H., Chatterjee S., Berger N.A. Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression. Cancer Res. 55:1995;4029-4035.
130. Campos L., Rouault J.P., Sabido O.et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
131. Yunis J.J., Mayer M.G., Arnesen M.A.et al. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. New Engl J Med. 320:1989;1047-1054.
132. McDonnell T.J., Troncosco P., Brisbay S.M.et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
133. Ofner D., Riehemann K., Maier H.et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 72:1995;981-985.
134. Hellemans P., Vandam P.A., Weyler J.et al. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 72:1995;354-360.
135. Gasparini G., Barbareschi M., Doglioni C.et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1:1995;189-198.
136. Pezzella F., Turley H., Kuzu I.et al. Bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med. 329:1993;690-694.
137. Lock R.B., Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 56:1996;4006-4012.
138. Kamesaki S., Kamesaki H., Jorgensen T.J.et al. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events sebsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53:1993;4251-4256.
139. Witte O.N. Role of the BCR-ABL oncogene in human leukemia: Fifteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 53:1993;485-489.
140. Bedi A., Zehnbauer B.A., Barber J.P.et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:1994;2038-2044.
141. McGahon A., Bissonnette R., Schmitt M.et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1994;1179-1187.
142. Griffin J.D. Hemopoietins in oncology: factoring out myelosuppression. J Clin Oncol. 7:1989;151-155.
143. Griffin J.D., Young D., Herrmann F.et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood. 67:1986;1448-1453.
144. Hoang T., Nara N., Wong G.et al. Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia. Blood. 68:1986;313-316.
145. Mitjavila M.T., Villeval J.L., Cramer P.et al. Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. Blood. 70:1987;965-973.
146. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
147. Clarkson B., Ohkita T., Ota K.et al. Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. J Clin Invest. 46:1967;506-529.
148. Todo A. Proliferation and differentiation of hematopoietic cells in hematologic disorders. II. In vitro radioautographic study of leukemic cells. Acta Haematol Jpn. 31:1968;932-946.
149. Strander H., Einhorn S. Interferons and the tumor cell. Biotherapy. 8:1996;213-218.
150. Osborne B.A., Schwartz L.M. Cell death suffers a TKO. Bioessays. 17:1995;557-559.
151. Taniguchi T., Harada H., Lamphier M. Regulation of the interferon system and cell growth by the IRF transcription factors. J Cancer Res Clin Oncol. 121:1995;516-520.
152. Alevizopoulos A., Mermod N. Transforming growth factor-beta: the breaking open of a black box. Bioessays. 19:1997;581-591.
153. Fischer G., Kent S.C., Joseph L.et al. Lymphoma models for B cell activation and tolerance. X. Anti-mu-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc. J Exp Med. 179:1994;221-228.
154. Kip1 mRNA and protein in murine B cells. J Immunol. 160:1998;770-777.